Skip to main content
GYRE logo

Gyre Therapeutics, Inc. (GYRE) Stock Price & Analysis

Gyre Therapeutics, Inc. (GYRE) — MoonshotScore 34/100 (Weak band), calculated Nov 18, 2026. Price $4.52 (+4.15%), as of the Nov 19, 2026 trading session; market cap $495M.

Educational signal · not a buy or sell recommendation · How to read this

$4.52 +$0.18 (+4.15%) Market Cap $495M

Gyre Therapeutics, Inc. · GYRE · NASDAQ

Gyre Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing anti-inflammatory and anti-fibrotic drugs.

Price as of Nov 19, 2026

Key Statistics

34 of 100

MoonshotScore v2 · Gyre Therapeutics (GYRE)

Weak
Business Quality Solid (67)
Financial Safety Strained (25)
Valuation Full (53)
Growth Durability Fading (28)
Momentum Slipping (39)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A strained balance sheet, weak growth and a full valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Strained; Valuation: Full; Growth Durability: Fading; Momentum: Slipping.

  • quarterly revenue $33M (Q3 FY2026, quarter ended Sep 30, 2026)
  • EPS beat 3 of the last 8 reports
  • Altman Z 8.28 · Piotroski F 1

Holding back: balance-sheet strain, soft growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for GYRE (57 recorded, newest six shown)
RecordedScoreBand
34Weak
35Weak
34Weak
34Weak
34Weak
34Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$4.52
Change on the day+4.15%
52-week range$3.97 – $9.14
Market capitalisation$495M—
Price / earnings (trailing)129.11
Shares traded on the day268.9K

Price & events

Other perspectives

Council score for Gyre Therapeutics (GYRE): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Weak
Valuation Neutral
Growth Durability Weak
Momentum Weak

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Sep 7, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Overvalued
Profit Margin Weak
Revenue Growth Moderate
Debt/Equity Strong
ROE Neutral
Gross Margin Strong

Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Apr 29, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Gyre Therapeutics (GYRE), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Gyre Therapeutics, Inc. (GYRE) is listed on NASDAQ. It employs 625 people and is led by Ying Luo. In Q3 FY2026 it reported revenue of $33M and net income of -$4M. The market values it at $495M.

2 · Latest results

What do the latest results show for Gyre Therapeutics (GYRE)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $33M. Against analyst estimates the company has EPS beat 3 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$33M-$4M-$0.04 (diluted)
Q2 FY2026$29M-$11M-$0.12 (diluted)
Q1 FY2026$23M-$9M-$0.10 (diluted)
Q4 FY2025$37M-$2M-$0.02 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Gyre Therapeutics (GYRE)?

Short answer · as of

What is holding it back is balance-sheet strain, soft growth. The distress and quality screens read Altman Z 8.28 · Piotroski F 1. Trailing ratios: ROE -22.4% · ROA -12.4% · current ratio 4.32 · earnings yield -5.5% · free-cash-flow yield -5.5%.

Data-derived red flags

  • Negative return on equity (-22.4%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
5 · Peer comparison

How does Gyre Therapeutics compare with its peers?

Short answer

Gyre Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Innoviva, Inc. (INVA) Same industry, near in market value$18.40 Nov 18, 2026$1.31B96 5-pillar Nov 18, 2026
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.07 Nov 19, 2026$540M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.06 Nov 19, 2026$258M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$12.17 Nov 19, 2026$861M69 5-pillar Nov 18, 2026
LB Pharmaceuticals Inc (LBRX) Same industry, near in market value$40.04 Nov 19, 2026$1.30B69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.28 Nov 19, 2026$545M68 5-pillar Nov 18, 2026
Erasca, Inc. (ERAS) Named competitor$14.22 Nov 19, 2026$4.99B67 5-pillar Nov 18, 2026
Vor Biopharma, Inc. (VOR) Same industry, near in market value$18.52 Nov 19, 2026$1.14B66 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$30.78 Nov 19, 2026$1.03B64 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.14 Nov 19, 2026$796M63 5-pillar Nov 18, 2026
Gyre Therapeutics (GYRE) — this page$4.52$495M34

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held GYRE in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported GYRE in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What Investors Ask About Gyre Therapeutics (GYRE)

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

What does the MoonshotScore mean for GYRE?

GYRE carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is GYRE a good stock to buy?

Stock Expert AI does not rate GYRE buy, sell or hold. Gyre Therapeutics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the GYRE stock price today?

The last price recorded for Gyre Therapeutics, Inc. (GYRE), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the key factors to evaluate for GYRE?

Gyre Therapeutics, Inc. (GYRE) holds a MoonshotScore in the low range. To weigh it, start with the trailing P/E under Price & valuation on this page. Analysts target $17.00 (+276%). ETUARY (Pirfenidone) is approved for idiopathic pulmonary fibrosis, providing a stable revenue stream. Not financial advice.

How frequently does GYRE data refresh on this page?

GYRE's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven GYRE's recent stock price performance?

Gyre Therapeutics, Inc. (GYRE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Approved product (ETUARY) for idiopathic pulmonary fibrosis. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider GYRE overvalued or undervalued right now?

The trailing P/E of Gyre Therapeutics, Inc. (GYRE) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of GYRE?

Fractional-share availability for Gyre Therapeutics, Inc. (GYRE) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

How can I track GYRE's earnings and financial reports?

Gyre Therapeutics, Inc. (GYRE) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for GYRE earnings announcements.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 16 figures on this page — 8 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.